Moleculin Biotech, Inc. (NasdaqCM: MBRX)
Health Care · Biotechnology · US
$0.62
+4.77% today · -95.9% 1Y
Moleculin Biotech, Inc. (NasdaqCM: MBRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $11.55M and employs 17 people.
Over the last twelve months the share price has lost 95.9%, trading between 0.16 and 15.75.
Tweenvest scores Moleculin Biotech, Inc. across four factors: quality 26/100. Its strongest factor is quality.
MBRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.55M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -9.60
- Dividend yield
- —
- Beta (5Y)
- 1.83
- 52-week high
- $15.75
- 52-week low
- $0.16
- Avg volume (3M)
- —
- Shares outstanding
- 19.48M
- Employees
- 17
- Next earnings
- —
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
- ISIN
- US60855D4088
- Founded
- 2015
- Listed since
- Jun 2, 2016
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.39 | +0.23% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.50 | -0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $154.90 | -2.47% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.